Sugi Predict

Sugi Predict / Compounds / SCHEMBL10154525

SCHEMBL10154525

SCHEMBL10154525

CC(CI)(N=C=S)c1ccc(Cl)cc1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ MIF P14174 2/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.34
▸ BCL2 P10415 1/20 0.33
▸ CYP19A1 P11511 3/20 0.33
▸ SLC6A2 P23975 1/20 0.32
▸ HTR2A P28223 1/20 0.32
▸ SLC6A4 P31645 1/20 0.32
▸ HRH1 P35367 1/20 0.32
▸ HTR2B P41595 1/20 0.32
▸ CHRNA4 P43681 1/20 0.32
▸ SLC6A3 Q01959 1/20 0.32
▸ POLB P06746 1/20 0.31
▸ TSHR P16473 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ HIF1A Q16665 1/20 0.31
▸ GABRA1 P14867 1/20 0.30
▸ GABRB2 P47870 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14980687 0.76 MIF (0.33) KMT2AMEN1MIFCYP19A1
SCHEMBL14143802 0.74 MEN1 (0.34) KMT2AMEN1MIFNPSR1SLC6A4
SCHEMBL3575673 0.74 KMT2A (0.39) KMT2AMEN1MIFNPSR1BCL2
SCHEMBL21945875 0.69 TSHR (0.37) POLBTSHRGABRA1GABRB2
SCHEMBL25119687 0.68 CYP19A1 (0.37) KMT2AMEN1MIFNPSR1CYP19A1
SCHEMBL21671255 0.68 NPC1 (0.40) POLBMAPK1GABRA1GABRB2
SCHEMBL10193733 0.66 ESR1 (0.43) KMT2AMEN1MIFNPSR1BCL2
SCHEMBL28027917 0.64 CYP2C19 (0.36) KMT2ATSHRMAPK1HIF1A
SCHEMBL25402014 0.64 RAPGEF3 (0.32) KMT2AMEN1SLC6A2SLC6A4SLC6A3
SCHEMBL6675119 0.64 MIF (0.31) MIFTSHRGABRA1GABRB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2597087-B1 Dihydrooxazine and tetrahydropyrimidine derivatives as BACE 1 inhibitors SHIONOGI & CO (JP) 2016-03-30 — — EP disclosed
US-20150210680-A1 AMINODIHYDROTHIAZINE DERIVATIVES SHIONOGI & CO (JP) 2015-07-30 — — US disclosed
US-20150210680-A1 AMINODIHYDROTHIAZINE DERIVATIVES SHIONOGI & CO (JP) 2015-07-30 — — US disclosed
US-9029358-B2 Aminodihydrothiazine derivatives SHIONOGI & CO., LTD. (JP) 2015-05-12 — — US disclosed
US-9029358-B2 Aminodihydrothiazine derivatives SHIONOGI & CO., LTD. (JP) 2015-05-12 — — US disclosed
US-8895548-B2 Pharmaceutical composition for treating alzheimer's disease SHIONOGI & CO., LTD. (JP) 2014-11-25 — — US disclosed
US-8895548-B2 Pharmaceutical composition for treating alzheimer's disease SHIONOGI & CO., LTD. (JP) 2014-11-25 — — US disclosed
US-8815851-B2 Aminodihydrothiazine derivatives SHIONOGI & CO., LTD. (JP) 2014-08-26 — — US disclosed
US-8815851-B2 Aminodihydrothiazine derivatives SHIONOGI & CO., LTD. (JP) 2014-08-26 — — US disclosed
EP-1942105-B1 AMINODIHYDROTHIAZINE DERIVATIVE SHIONOGI & CO (JP) 2014-04-16 — — EP disclosed
US-8546380-B2 Aminodihydrothiazine derivatives SHIONOGI & CO., LTD. (JP) 2013-10-01 — — US disclosed
US-8546380-B2 Aminodihydrothiazine derivatives SHIONOGI & CO., LTD. (JP) 2013-10-01 — — US disclosed
EP-2612854-A1 Aminothiazolidine and aminotetrahydrothiazepine derivatives as BACE 1 inhibitors Shionogi&Co., Ltd. (JP) 2013-07-10 — — EP disclosed
US-20130158260-A1 AMINODIHYDROTHIAZINE DERIVATIVES SHIONOGI & CO., LTD. (JP) 2013-06-20 — — US disclosed
US-20130158260-A1 AMINODIHYDROTHIAZINE DERIVATIVES SHIONOGI & CO., LTD. (JP) 2013-06-20 — — US disclosed
US-8173642-B2 Aminodihydrothiazine derivatives SHIONOGI & CO., LTD. (JP) 2012-05-08 — — US disclosed
US-20120022249-A1 AMINODIHYDROTHIAZINE DERIVATIVES SHIONOGI & CO., LTD. (JP) 2012-01-26 — — US disclosed
US-20120016116-A1 AMINODIHYDROTHIAZINE DERIVATIVES SHIONOGI & CO., LTD. (JP) 2012-01-19 — — US disclosed
US-20100160290-A1 PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE SHIONOGI & CO., LTD. (JP) 2010-06-24 — — US disclosed
US-20090082560-A1 AMINODIHYDROTHIAZINE DERIVATIVES SHIONOGI & CO., LTD. (JP) 2009-03-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120016116-A1 AMINODIHYDROTHIAZINE DERIVATIVES BACE1, BACE2, APP KMT2A 870/4885MEN1 3038/4885MIF 2835/4885
US-20100160290-A1 PHARMACEUTICAL COMPOSITION FOR TREATING ALZHEIMER'S DISEASE NR1H2, NR1H3, NR0B1 KMT2A 1106/4885MEN1 3119/4885MIF 4239/4885
US-20130158260-A1 AMINODIHYDROTHIAZINE DERIVATIVES BACE1, BACE2, APP KMT2A 1184/4885MEN1 2266/4885MIF 2521/4885
US-20120022249-A1 AMINODIHYDROTHIAZINE DERIVATIVES BACE1, BACE2, APP KMT2A 870/4885MEN1 3038/4885MIF 2835/4885
US-20150210680-A1 AMINODIHYDROTHIAZINE DERIVATIVES BACE1, BACE2, APP KMT2A 870/4885MEN1 3038/4885MIF 2835/4885
US-20090082560-A1 AMINODIHYDROTHIAZINE DERIVATIVES BACE1, BACE2, APP KMT2A 870/4885MEN1 3038/4885MIF 2835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.